Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BARS13 RSV Vaccine in Elderly Adults
NCT04681833Phase 2Completed
- Sponsor
- Advaccine Biotechnology
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of BARS13 in respiratory syncytial virus infection (RSV), sponsored by Advaccine Biotechnology. Started May 2021; status: completed.
02
Drugs
BARS13
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04681833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681833.